RxDoctor Payments Data

Peter Rosenberg, MD

Internal Medicine · Manhasset, NYNPI 1366438228

Payments from drug & device makers

$3,261in general payments, 2019–2025

Across 161 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$847
  • Pfizer$505
  • AstraZeneca$343
  • Boehringer Ingelheim$338
  • E.r. Squibb & Sons, L.L.C.$293
  • AbbVie$238
  • plus $698 from 13 others

What the payments were for

  • Food & beverage$3,261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,261 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$205,833
Medicare patients
643
Services billed
3,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$257,908
XareltoRivaroxaban95$118,803
JanuviaSitagliptin Phosphate36$49,865
EntrestoSacubitril/Valsartan38$32,651
FarxigaDapagliflozin Propanediol31$31,668
Meprobamate21$9,647
SynthroidLevothyroxine Sodium112$8,455
LexaproEscitalopram Oxalate19$8,051
Atorvastatin Calcium562$5,298
Metoprolol Succinate373$5,220
Amlodipine Besylate704$4,563
Atenolol453$4,444
Levothyroxine Sodium366$4,276
Simvastatin439$4,246
Losartan Potassium413$3,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$505$257,908205 claims
Johnson & JohnsonXarelto$847$118,80395 claims
MerckJanuvia$23$49,86536 claims
NovartisEntresto$183$32,65138 claims
AstraZenecaFarxiga$343$31,66831 claims
AbbVieSynthroid, Lexapro$238$16,506131 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$4,276366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →